-
2
-
-
84900829967
-
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs
-
Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006.
-
(2014)
JAMA
, vol.311
, pp. 1998-2006
-
-
Kris, M.G.1
Johnson, B.E.2
Berry, L.D.3
-
3
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
-
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
-
4
-
-
84884736973
-
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
-
Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3327-3334
-
-
Sequist, L.V.1
Yang, J.C.2
Yamamoto, N.3
-
5
-
-
84896957081
-
Ceritinib in ALK-rearranged non-small-cell lung cancer
-
Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97.
-
(2014)
N Engl J Med
, vol.370
, pp. 1189-1197
-
-
Shaw, A.T.1
Kim, D.W.2
Mehra, R.3
-
6
-
-
84879071011
-
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
-
Shaw AT, Kim DW, Nakagawa K, et al, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
-
(2013)
N Engl J Med
, vol.368
, pp. 2385-2394
-
-
Shaw, A.T.1
Kim, D.W.2
Nakagawa, K.3
-
7
-
-
79952284127
-
Hallmarks of cancer: the next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
8
-
-
84857882376
-
Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?
-
Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther 2012;13:247-63.
-
(2012)
Cancer Biol Ther
, vol.13
, pp. 247-263
-
-
Aggarwal, C.1
Somaiah, N.2
Simon, G.3
-
9
-
-
34247468303
-
The potential of antiangiogenic therapy in non-small cell lung cancer
-
Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 2007;13:1961-70.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1961-1970
-
-
Giaccone, G.1
-
10
-
-
63749125392
-
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
-
Lohela M, Bry M, Tammela T, et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21:154-65.
-
(2009)
Curr Opin Cell Biol
, vol.21
, pp. 154-165
-
-
Lohela, M.1
Bry, M.2
Tammela, T.3
-
11
-
-
77549088772
-
Pathways mediating VEGF-independent tumor angiogenesis
-
Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010;21:21-6.
-
(2010)
Cytokine Growth Factor Rev
, vol.21
, pp. 21-26
-
-
Ferrara, N.1
-
13
-
-
33947732977
-
Angiogenesis: an organizing principle for drug discovery?
-
Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86.
-
(2007)
Nat Rev Drug Discov
, vol.6
, pp. 273-286
-
-
Folkman, J.1
-
15
-
-
14644440555
-
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
-
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1011-1027
-
-
Hicklin, D.J.1
Ellis, L.M.2
-
16
-
-
30744449235
-
Angiogenesis as a therapeutic target
-
Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
-
(2005)
Nature
, vol.438
, pp. 967-974
-
-
Ferrara, N.1
Kerbel, R.S.2
-
17
-
-
0034796595
-
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy
-
Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
-
(2001)
Nat Med
, vol.7
, pp. 987-989
-
-
Jain, R.K.1
-
18
-
-
33747855481
-
Comparing antibody and small-molecule therapies for cancer
-
Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-27.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 714-727
-
-
Imai, K.1
Takaoka, A.2
-
19
-
-
2942657615
-
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
-
Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2184-2191
-
-
Johnson, D.H.1
Fehrenbacher, L.2
Novotny, W.F.3
-
20
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
-
21
-
-
62449124416
-
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
-
Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1227-1234
-
-
Reck, M.1
von Pawel, J.2
Zatloukal, P.3
-
22
-
-
77951473661
-
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
-
Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9.
-
(2010)
Ann Oncol
, vol.21
, pp. 1804-1809
-
-
Reck, M.1
von Pawel, J.2
Zatloukal, P.3
-
23
-
-
84886385462
-
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)
-
Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 2013;31:3004-11.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3004-3011
-
-
Barlesi, F.1
Scherpereel, A.2
Rittmeyer, A.3
-
24
-
-
84905822586
-
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
-
Barlesi F, Scherpereel A, Gorbunova V, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 2014;25:1044-52.
-
(2014)
Ann Oncol
, vol.25
, pp. 1044-1052
-
-
Barlesi, F.1
Scherpereel, A.2
Gorbunova, V.3
-
25
-
-
84892454962
-
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer
-
Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:4349-57.
-
(2013)
J Clin Oncol
, vol.31
, pp. 4349-4357
-
-
Patel, J.D.1
Socinski, M.A.2
Garon, E.B.3
-
26
-
-
84926419605
-
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer
-
Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 2015;10:134-42.
-
(2015)
J Thorac Oncol
, vol.10
, pp. 134-142
-
-
Zinner, R.G.1
Obasaju, C.K.2
Spigel, D.R.3
-
27
-
-
84925706983
-
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer
-
Camidge DR, Berge EM, Doebele RC, et al. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol 2014;9:1532-9.
-
(2014)
J Thorac Oncol
, vol.9
, pp. 1532-1539
-
-
Camidge, D.R.1
Berge, E.M.2
Doebele, R.C.3
-
28
-
-
84906903314
-
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
-
Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384:665-73.
-
(2014)
Lancet
, vol.384
, pp. 665-673
-
-
Garon, E.B.1
Ciuleanu, T.E.2
Arrieta, O.3
-
29
-
-
84865721505
-
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer
-
Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012;30:3084-92.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3084-3092
-
-
Paz-Ares, L.G.1
Biesma, B.2
Heigener, D.3
-
30
-
-
84892165925
-
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer
-
Scagliotti GV, Felip E, Besse B, et al. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thorac Oncol 2013;8:1529-37.
-
(2013)
J Thorac Oncol
, vol.8
, pp. 1529-1537
-
-
Scagliotti, G.V.1
Felip, E.2
Besse, B.3
-
31
-
-
84863936062
-
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial
-
Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012;30:2070-8.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2070-2078
-
-
Scagliotti, G.V.1
Krzakowski, M.2
Szczesna, A.3
-
32
-
-
84894041073
-
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
-
Laurie SA, Solomon BJ, Seymour L, et al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer 2014;50:706-12.
-
(2014)
Eur J Cancer
, vol.50
, pp. 706-712
-
-
Laurie, S.A.1
Solomon, B.J.2
Seymour, L.3
-
33
-
-
84865095318
-
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1
-
Scagliotti GV, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012;30:2829-36.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2829-2836
-
-
Scagliotti, G.V.1
Vynnychenko, I.2
Park, K.3
-
34
-
-
84922341727
-
Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non-Small-Cell Lung Cancer
-
Ramalingam SS, Shtivelband M, Soo RA, et al. Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2015;33:433-41.
-
(2015)
J Clin Oncol
, vol.33
, pp. 433-441
-
-
Ramalingam, S.S.1
Shtivelband, M.2
Soo, R.A.3
-
35
-
-
77954035012
-
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
-
Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11:619-26.
-
(2010)
Lancet Oncol
, vol.11
, pp. 619-626
-
-
Herbst, R.S.1
Sun, Y.2
Eberhardt, W.E.3
-
36
-
-
84892967581
-
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
-
Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143-55.
-
(2014)
Lancet Oncol
, vol.15
, pp. 143-155
-
-
Reck, M.1
Kaiser, R.2
Mellemgaard, A.3
-
37
-
-
84903901969
-
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
-
Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014;17:471-94.
-
(2014)
Angiogenesis
, vol.17
, pp. 471-494
-
-
Vasudev, N.S.1
Reynolds, A.R.2
-
38
-
-
0030856731
-
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
-
Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
-
(1997)
Cancer Res
, vol.57
, pp. 4593-4599
-
-
Presta, L.G.1
Chen, H.2
O'Connor, S.J.3
-
39
-
-
84960175992
-
-
2012 ASCO Annual Meeting. Chicago, Illinois, USA
-
Gridelli C, Bennouna J, De Castro J, et al. AvaALL: Open-label randomized phase IIIb trial evaluating the efficacy and safety of standard of care with or without continuous bevacizumab (BV) treatment beyond disease progression in patients (pts) with advanced nonsquamous non-small cell lung cancer (NSCLC) after first-line (1L) treatment with BV plus platinum-doublet chemotherapy (CT). 2012 ASCO Annual Meeting. Chicago, Illinois, USA, 2012.
-
(2012)
AvaALL: Open-label randomized phase IIIb trial evaluating the efficacy and safety of standard of care with or without continuous bevacizumab (BV) treatment beyond disease progression in patients (pts) with advanced nonsquamous non-small cell lung cancer (NSCLC) after first-line (1L) treatment with BV plus platinum-doublet chemotherapy (CT)
-
-
Gridelli, C.1
Bennouna, J.2
De Castro, J.3
-
40
-
-
33748369295
-
Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial
-
Wakelee HA, Schiller JH, Gandara DR. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial. Clin Lung Cancer 2006;8:18-21.
-
(2006)
Clin Lung Cancer
, vol.8
, pp. 18-21
-
-
Wakelee, H.A.1
Schiller, J.H.2
Gandara, D.R.3
-
41
-
-
84908127948
-
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
-
Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014;15:1236-44.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1236-1244
-
-
Seto, T.1
Kato, T.2
Nishio, M.3
-
42
-
-
84918818218
-
The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria
-
Gentzler RD, Yentz SE, Johnson ML, et al. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria. Cancer 2014;120:3853-8.
-
(2014)
Cancer
, vol.120
, pp. 3853-3858
-
-
Gentzler, R.D.1
Yentz, S.E.2
Johnson, M.L.3
-
43
-
-
84901595989
-
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015)
-
Mok T, Gorbunova V, Juhasz E, et al. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). J Thorac Oncol 2014;9:848-55.
-
(2014)
J Thorac Oncol
, vol.9
, pp. 848-855
-
-
Mok, T.1
Gorbunova, V.2
Juhasz, E.3
-
44
-
-
84892852372
-
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
-
Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-9.
-
(2014)
Lancet
, vol.383
, pp. 31-39
-
-
Fuchs, C.S.1
Tomasek, J.2
Yong, C.J.3
-
45
-
-
84908139963
-
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
-
Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-35.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1224-1235
-
-
Wilke, H.1
Muro, K.2
Van Cutsem, E.3
-
46
-
-
84933673498
-
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
-
Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16:499-508.
-
(2015)
Lancet Oncol
, vol.16
, pp. 499-508
-
-
Tabernero, J.1
Yoshino, T.2
Cohn, A.L.3
-
47
-
-
77649213706
-
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2
-
Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28:780-7.
-
(2010)
J Clin Oncol
, vol.28
, pp. 780-787
-
-
Spratlin, J.L.1
Cohen, R.B.2
Eadens, M.3
-
48
-
-
84924207092
-
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer
-
Doebele RC, Spigel D, Tehfe M, et al. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer 2015;121:883-92.
-
(2015)
Cancer
, vol.121
, pp. 883-892
-
-
Doebele, R.C.1
Spigel, D.2
Tehfe, M.3
-
49
-
-
77951639655
-
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
-
Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-42.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1835-1842
-
-
Scagliotti, G.1
Novello, S.2
von Pawel, J.3
-
50
-
-
84890663541
-
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial
-
Blumenschein GR Jr, Saintigny P, Liu S, et al. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res 2013;19:6967-75.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 6967-6975
-
-
Blumenschein, G.R.1
Saintigny, P.2
Liu, S.3
-
51
-
-
84873354408
-
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation
-
Dingemans AM, Mellema WW, Groen HJ, et al. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation. Clin Cancer Res 2013;19:743-51.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 743-751
-
-
Dingemans, A.M.1
Mellema, W.W.2
Groen, H.J.3
-
52
-
-
84960128922
-
-
2013 ASCO Annual Meeting. Chicago, Illinois, USA
-
Gentzler RD, Kaklamani VG, Worden R, et al. Phase (Ph) I study of pazopanib (P) in combination with vinorelbine (V) in patients with metastatic non-small cell lung cancer (mNSCLC) and breast cancer (mBC). 2013 ASCO Annual Meeting. Chicago, Illinois, USA, 2013.
-
(2013)
Phase (Ph) I study of pazopanib (P) in combination with vinorelbine (V) in patients with metastatic non-small cell lung cancer (mNSCLC) and breast cancer (mBC)
-
-
Gentzler, R.D.1
Kaklamani, V.G.2
Worden, R.3
-
53
-
-
84893413347
-
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer
-
Heist RS, Wang X, Hodgson L, et al. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2014;9:214-21.
-
(2014)
J Thorac Oncol
, vol.9
, pp. 214-221
-
-
Heist, R.S.1
Wang, X.2
Hodgson, L.3
-
54
-
-
73949092851
-
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
-
Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010;28:49-55.
-
(2010)
J Clin Oncol
, vol.28
, pp. 49-55
-
-
Goss, G.D.1
Arnold, A.2
Shepherd, F.A.3
-
55
-
-
79955795090
-
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
-
Blumenschein GR Jr, Kabbinavar F, Menon H, et al. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2011;22:2057-67.
-
(2011)
Ann Oncol
, vol.22
, pp. 2057-2067
-
-
Blumenschein, G.R.1
Kabbinavar, F.2
Menon, H.3
-
56
-
-
80051801904
-
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer
-
Tan EH, Goss GD, Salgia R, et al. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011;6:1418-25.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1418-1425
-
-
Tan, E.H.1
Goss, G.D.2
Salgia, R.3
-
57
-
-
79952742483
-
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial
-
de Boer RH, Arrieta O, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011;29:1067-74.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1067-1074
-
-
de Boer, R.H.1
Arrieta, O.2
Yang, C.H.3
-
58
-
-
79952748468
-
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer
-
Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29:1059-66.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1059-1066
-
-
Natale, R.B.1
Thongprasert, S.2
Greco, F.A.3
-
59
-
-
84861720010
-
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)
-
Lee JS, Hirsh V, Park K, et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012;30:1114-21.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1114-1121
-
-
Lee, J.S.1
Hirsh, V.2
Park, K.3
|